Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Stephanie Yasmin Brule(Ottawa Hospital), Rachel Goodwin(University of Ottawa), Chris J. O’Callaghan(Unknown), Craig Underhill(AstraZeneca (United Kingdom)), Desmond Yip(Calvary Hospital), Dongsheng Tu(Ontario Institute for Cancer Research), Derek J. Jonker(University of Ottawa), Christos S. Karapetis(Clínica Alemana), Niall C. Tebbutt(Austin Health), Malcolm J. Moore(University Health Network), Ralph Wong(CancerCare Manitoba), John Zalcberg(Monash Health)
Cited by 337
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k